Preoperative serum macrophage activated biomarkers soluble mannose receptor (sMR) and soluble haemoglobin scavenger receptor (sCD163), as novel markers for the diagnosis and prognosis of gastric cancer

Ding,Dongbing; Song,Yang; Yao,Yao; Zhang,Songbai

doi:10.3892/ol.2017.6547

Preoperative serum macrophage activated biomarkers soluble mannose receptor (sMR) and soluble haemoglobin scavenger receptor (sCD163), as novel markers for the diagnosis and prognosis of gastric cancer

Authors:
- Dongbing Ding
- Yang Song
- Yao Yao
- Songbai Zhang
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Jingmen First People's Hospital, Jingmen, Hubei 448000, P.R. China, Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian 116023, P.R. China, Department of Ophthalmology, Jingmen First People's Hospital, Jingmen, Hubei 448000, P.R. China
Published online on: July 8, 2017 https://doi.org/10.3892/ol.2017.6547
Pages: 2982-2990
Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Soluble mannose receptor (sMR) and soluble haemoglobin scavenger receptor (sCD163) are macrophage activation markers which have previously been demonstrated to be increased in patients with inflammation, auto‑immunity and malignancies. To investigate the clinical diagnostic and prognostic significance of preoperative serum sMR and sCD163, the present study investigated 143 gastric cancer (GC) patients, 66 subjects with benign gastric disease and 59 healthy controls, using an ELISA assay. Preoperative serum levels of sMR and sCD163 ranged from 0.165 to 0.885 µg/ml (median=0.374 µg/ml) and from 0.291 to 1.760 µg/ml (median=0.628 µg/ml) in GC patients, respectively. The expression levels of sMR and sCD163 were elevated compared with all controls (P<0.0001). Receiver operating characteristic analyses suggested that the optimum diagnostic cut‑offs for sMR and sCD163 were 0.3405 µg/ml [area under curve (AUC) 0.7284, sensitivity 61.54%, and specificity 73.60%] and 0.6645 µg/ml (AUC 0.7766, sensitivity 53.85%, and specificity 86.40%), respectively. Notably, the measurement of serum sMR and sCD163 levels in conjugation, markedly enhanced the diagnostic accuracy (AUC 0.8490, sensitivity 70.63% and specificity 84.00%). Preoperative serum sMR and sCD163 levels correlated significantly with serum carcinoembryonic antigen, CA199, CA724 and CA125 concentrations in GC patients (P<0.05), however this association was not observed with sMR and CA724. High preoperative serum sMR and sCD163 levels correlated significantly with shorter overall survival (P=0.0041; P<0.0001, respectively) and were demonstrated to act as adverse prognostic factors (P=0.006; P<0.001, respectively). Furthermore, preoperative serum sMR and sCD163 levels correlated positively with the degree of lymphatic and distant metastasis of GC. In conclusion, preoperative serum sMR and sCD163 may be novel diagnostic and prognostic markers for GC and further studies are required in order to elucidate the underlying molecular mechanisms of sMR and CD163 in the development and progression of GC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Zhou M, Wang H, Zhu J, Chen W, Wang L, Liu S, Li Y, Wang L, Liu Y, Yin P, et al: Cause-specific mortality for 240 causes in China during 1990–2013: A systematic subnational analysis for the global burden of disease study 2013. Lancet. 387:251–272. 2016. View Article : Google Scholar : PubMed/NCBI
3	Cohen DJ and Leichman L: Controversies in the treatment of local and locally advanced gastric and esophageal cancers. J Clin Oncol. 33:1754–1759. 2015. View Article : Google Scholar : PubMed/NCBI
4	Hu Y, Fang JY and Xiao SD: Can the incidence of gastric cancer be reduced in the new century? J Dig Dis. 14:11–15. 2013. View Article : Google Scholar : PubMed/NCBI
5	Martinez-Pomares L: The mannose receptor. J Leukoc Biol. 92:1177–1186. 2012. View Article : Google Scholar : PubMed/NCBI
6	Irjala H, Alanen K, Grénman R, Heikkilä P, Joensuu H and Jalkanen S: Mannose receptor (MR) and common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1 direct the binding of cancer cells to the lymph vessel endothelium. Cancer Res. 63:4671–4676. 2003.PubMed/NCBI
7	Rødgaard-Hansen S, Rafique A, Christensen PA, Maniecki MB, Sandahl TD, Nexø E and Møller HJ: A soluble form of the macrophage-related mannose receptor (MR/CD206) is present in human serum and elevated in critical illness. Clin Chem Lab Med. 52:453–461. 2014. View Article : Google Scholar : PubMed/NCBI
8	Rødgaard-Hansen S, Rafique A, Weis N, Wejse C, Nielsen H, Pedersen SS, Møller HJ and Kronborg G: Increased concentrations of the soluble mannose receptor in serum from patients with pneumococcal bacteraemia, and prediction of survival. Infect Dis (Lond). 47:203–208. 2015. View Article : Google Scholar : PubMed/NCBI
9	Kjærgaard AG, Rødgaard-Hansen S, Dige A, Krog J, Møller HJ and Tønnesen E: Monocyte expression and soluble levels of the haemoglobin receptor (CD163/sCD163) and the mannose receptor (MR/sMR) in septic and critically ill non-septic ICU patients. PLoS One. 9:e923312014. View Article : Google Scholar : PubMed/NCBI
10	Andersen MN, Andersen NF, Rødgaard-Hansen S, Hokland M, Abildgaard N and Møller HJ: The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR/sCD206): Implications in multiple myeloma. Leuk Res. 39:971–975. 2015. View Article : Google Scholar : PubMed/NCBI
11	Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK and Moestrup SK: Identification of the haemoglobin scavenger receptor. Nature. 409:198–201. 2001. View Article : Google Scholar : PubMed/NCBI
12	Edge SB and Compton CC: The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
13	Møller HJ, Peterslund NA, Graversen JH and Moestrup SK: Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood. 99:378–380. 2002. View Article : Google Scholar : PubMed/NCBI
14	Karrasch T, Brünnler T, Hamer OW, Schmid K, Voelk M, Herfarth H and Buechler C: Soluble CD163 is increased in patients with acute pancreatitis independent of disease severity. Exp Mol Pathol. 99:236–239. 2015. View Article : Google Scholar : PubMed/NCBI
15	Kazankov K, Rode A, Simonsen K, Villadsen GE, Nicoll A, Møller HJ, Lim L, Angus P, Kronborg I, Arachchi N, et al: Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma. Scand J Clin Lab Invest. 76:64–73. 2016. View Article : Google Scholar : PubMed/NCBI
16	No JH, Moon JM, Kim K and Kim YB: Prognostic significance of serum soluble CD163 level in patients with epithelial ovarian cancer. Gynecol Obstet Invest. 75:263–267. 2013. View Article : Google Scholar : PubMed/NCBI
17	Nederby L, Roug AS, Knudsen SS, Skovbo A, Kjeldsen E, Moller HJ and Hokland M: Soluble CD163 as a prognostic biomarker in B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 56:3219–3221. 2015. View Article : Google Scholar : PubMed/NCBI
18	Andersen MN, Abildgaard N, Maniecki MB, Møller HJ and Andersen NF: Monocyte/macrophage-derived soluble CD163: A novel biomarker in multiple myeloma. Eur J Haematol. 93:41–47. 2014. View Article : Google Scholar : PubMed/NCBI
19	Weaver LK, Pioli PA, Wardwell K, Vogel SN and Guyre PM: Up-regulation of human monocyte CD163 upon activation of cell-surface Toll-like receptors. J Leukoc Biol. 81:663–671. 2007. View Article : Google Scholar : PubMed/NCBI
20	Yang AP, Liu J, Lei HY, Zhang QW, Zhao L and Yang GH: CA72-4 combined with CEA, CA125 and CA19-9 improves the sensitivity for the early diagnosis of gastric cancer. Clin Chim Acta. 437:183–186. 2014. View Article : Google Scholar : PubMed/NCBI
21	Nakata B, Hirakawa-YS Chung K, Kato Y, Yamashita Y, Maeda K, Onoda N, Sawada T and Sowa M: Serum CA125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma. Cancer. 83:2488–2492. 1998. View Article : Google Scholar : PubMed/NCBI
22	Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S and Kitayama J: Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer. 15:154–161. 2012. View Article : Google Scholar : PubMed/NCBI
23	Liang Y, Wang W, Fang C, Raj SS, Hu WM, Li QW and Zhou ZW: Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric cancer. Oncotarget. 7:49565–49573. 2016. View Article : Google Scholar : PubMed/NCBI
24	Liu X, Qiu H, Liu J, Chen S, Xu D, Li W, Zhan Y, Li Y, Chen Y, Zhou Z and Sun X: Combined preoperative concentrations of CEA, CA 19-9, and 72-4 for predicting outcomes in patients with gastric cancer after curative resection. Oncotarget. 7:35446–35453. 2016. View Article : Google Scholar : PubMed/NCBI
25	Sun Z and Zhang N: Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. World J Surg Oncol. 12:3972014. View Article : Google Scholar : PubMed/NCBI
26	Kwon OK, Yu W and Chung H: Prognostic value of postoperative CA19-9 normalization in patients with advanced gastric cancer. Hepatogastroenterology. 60:240–243. 2013.PubMed/NCBI
27	Shida A, Mitsumori N, Nimura H, Takano Y, Iwasaki T, Fujisaki M, Takahashi N and Yanaga K: Prediction of lymph node metastasis and sentinel node navigation surgery for patients with early-stage gastric cancer. Word J Gastroenterol. 22:7431–7439. 2016. View Article : Google Scholar
28	Marttila-Ichihara F, Turja R, Miiluniemi M, Karikoski M, Maksimow M, Niemelä J, Martinez-Pomares L, Salmi M and Jalkanen S: Macrophage mannose receptor on lymphatics controls cell trafficking. Blood. 112:64–72. 2008. View Article : Google Scholar : PubMed/NCBI